Canagliflozin (invokana), a novel oral agent for type-2 diabetes.
Article Details
- CitationCopy to clipboard
Sarnoski-Brocavich S, Hilas O
Canagliflozin (invokana), a novel oral agent for type-2 diabetes.
P T. 2013 Nov;38(11):656-66.
- PubMed ID
- 24391386 [ View in PubMed]
- Abstract
Not Available
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Canagliflozin UDP-glucuronosyltransferase 1-9 Protein Humans UnknownSubstrateDetails Canagliflozin UDP-glucuronosyltransferase 2B4 Protein Humans UnknownSubstrateDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareCanagliflozinPhenytoin The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin. CanagliflozinFosphenytoin The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.